Novo Nordisk beats expectations – upgrades outlook

Pharmaceutical company Novo Nordisk increased its net result in Q1 compared with the same period last year, thereby beating analyst expectations. Now, it's upgrading its outlook for 2021.

Photo: Novo Nordisk Pharmatech/PR

In the first three months of the year, Danish pharmaceutical company Novo Nordisk's net result increased steadily, while its top line has landed at the same level as last year, according to the firm's interim report for Q1 which was published Monday morning.

The report also reveals that the firm plans to upgrade its outlook for 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs